Natural Capsules Ltd

Natural Capsules Ltd has a debt-to-equity ratio of 0.45 and a current ratio of 1.3, indicating moderate liquidity and a balanced capital structure. However, the company's free cash flow is negative at -348.95 million INR, and capital expenditures are -446.30 million INR, suggesting significant reinvestment in operations. The company's cash and equivalents are minimal at 1,000 INR, which raises concerns about short-term liquidity. In terms of profitability, the company's return on equity is 0.27% and return on assets is 0.15%, both of which are below the industry median for pharmaceutical companies. This suggests that the company is underperforming in generating returns relative to its equity and asset base. Natural Capsules Ltd operates in a single business segment focused on capsule shell manufacturing and API production. The company's revenue is primarily derived from domestic and international markets, with no disclosed geographic revenue concentration. However, the company's reliance on a single product line and geographic exposure to India may pose risks in the event of regulatory or economic disruptions. The company's revenue for the latest period is 1,692.06 million INR. While the outlook for the current fiscal year is not explicitly provided, the company's operating income of 82.81 million INR and net income of 6.17 million INR suggest a modest profit margin. The company's growth trajectory is constrained by its low profitability and significant capital expenditures. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The company's dilution potential is low, and no significant adjustments have been applied to its valuations. Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company continues to focus on its core business of capsule shell manufacturing and API production through its subsidiary, Natural Biogenex Private Limited.